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Abstract Atherosclerosis is the major cause of cardiovas-
cular disease, which still has the leading position in
morbidity and mortality in the Western world. Many risk
factors and pathobiological processes are acting together in
the development of atherosclerosis. This leads to different
remodelling stages (positive and negative) which are both
associated with plaque physiology and clinical presentation.
The different remodelling stages of atherosclerosis are
explained with their clinical relevance. Recent advances in
basic science have established that atherosclerosis is not
only a lipid storage disease, but that also inflammation has
a fundamental role in all stages of the disease. The
molecular events leading to atherosclerosis will be exten-
sively reviewed and described. Further on in this review
different modalities and their role in the different stages of
atherosclerosis will be discussed. Non-nuclear invasive
imaging techniques (intravascular ultrasound, intravascular
MRI, intracoronary angioscopy and intravascular optical
coherence tomography) and non-nuclear non-invasive
imaging techniques (ultrasound with Doppler flow,
electron-bean computed tomography, coronary computed
tomography angiography, MRI and coronary artery MR
angiography) will be reviewed. After that we focus on
nuclear imaging techniques for detecting atherosclerotic
plaques, divided into three groups: atherosclerotic lesion
components, inflammation and thrombosis. This emerging
area of nuclear imaging techniques can provide measures of
biological activity of atherosclerotic plaques, thereby
improving the prediction of clinical events. As we will
see in the future perspectives, at present, there is no special
tracer that can be called the diagnostic tool to diagnose
prospective stroke or infarction in patients. Nevertheless,
we expect such a tracer to be developed in the next few
years and maybe, theoretically, it could even be used for
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Introduction
Cardiovascular disease (CVD) is the leading cause of
morbidity and mortality in the Western world and is
responsible for approximately 50% of all deaths in the
USA, Europe and Japan [1]. CVD comprises three major
areas, being coronary heart diseases (myocardial infarction,
angina, heart failure and coronary death), cerebrovascular
diseases (stroke, transient ischaemic attacks) and peripheral
vascular diseases (claudicatio intermittens, gangrene). CVD
is common in the general population, affecting the majority
of adults past the age of 60 years. The lifetime risk of
coronary heart disease (CHD) in individuals initially free of
CHD is 49% in men and 32% in women at age 40. The
lifetime risk is also appreciable in those free of CHD at age
70: 35% in men and 24% in women [2].
Atherosclerosis is the major cause of cardiovascular
disease [3]. A variety of risk factors and pathobiological
processes, often acting together, are associated with an
increased risk for developing atherosclerosis in the coro-
nary and peripheral vasculature. A major pathobiological
process central to the pathogenesis of atherosclerosis is the
deposition of cholesterol in the arterial wall [4]. Nearly all
lipoproteins are involved in this process, including choles-
terol carried by very low-density (VLDL), remnant lip-
oproteins [5] and low-density lipoproteins (LDL),
particularly the small, dense form [6]. Conversely, choles-
terol is carried away from the arterial wall by high-density
lipoprotein (HDL) [7]. Therefore, it is well recognized that
abnormalities in lipoprotein profile, both inherited or
acquired, are the most important cause of premature
atherosclerosis [8]. Consistently, several large-scale trials
have demonstrated that the reduction of LDL by either diet
or drugs is followed by a significant reduction of ischaemic
cardiovascular events [9–11].
Other major, modifiable factors are diabetes mellitus,
hypertension, cigarette smoking (active and passive), obesity
and physical inactivity[12–14]. Family history of premature
CHD (genetic predisposition), age and gender are not
modifiable independent risk factors for atherosclerosis [12].
In addition to the above-mentioned major risk factors,
clinical and epidemiological studies have indicated that
once an atherosclerotic plaque reaches a certain stage of
development, the plaque itself becomes a risk factor for
future vascular events [15]. This is because existing plaques
can undergo rupture or erosion, thus favouring the
formation of an occluding thrombus [16]. This is clearly
demonstrated by follow-up studies on patients undergoing
coronary angiograms revealing that the probability of future
coronary events relates to the extent of coronary atheroscle-
rosis [17]. The more extensive the burden of atherosclerosis
is, the greater is the frequency of plaque rupture [15]. As
the severity of atherosclerosis rises with age, the usual way
of estimating plaque burden in the clinical setting is to use
age as a surrogate marker. This approach has been accepted
for primary prevention [18]; however, once significant
atherosclerosis has been definitely identified, the patient is
often designated as having preclinical disease, without
symptoms. As a result, plaque burden has to be integrated
into risk assessment in asymptomatic patients [15].
In recent years several techniques for estimating the
severity of atherosclerotic burden have been investigated.
The aim of this article is to review advantages and
disadvantages of these techniques, with special attention to
the molecular imaging of atherosclerosis. In the last couple of
years our knowledge of the molecular mechanisms of
atherosclerosis has greatly expanded. This led to the recogni-
tion that the rupture of vulnerable plaques is critical in
converting asymptomatic atherosclerosis to a clinical event.
Therefore, in this article particular attention will be dedicated
tothoseproceduresdesignedtoexplorethe“functionalstatus”
of the atherosclerotic plaque. The hypothesis is that measure-
ment of plaque activity would improve the global risk
assessment of patients with atherosclerosis, thus allowing
more cost-effective risk reduction treatments.
Remodelling stages of atherosclerosis
The exact mechanisms by which atherogenic factors act are
only partially known. However there are indications that
they primarily alter the protective function of endothelium
thus favouring the deposit of lipids and monocytes/macro-
phages into the vascular wall. Atherosclerosis develops
over the course of 50 years, beginning in the early teenage
years. Initial, fatty streaks in the arterial intima are seen in
childhood and adolescence [19].
In the first steps, i.e. formation of stable plaque, an
innate immune response plays a pivotal role in determining
the evolution of the lesion. In particular monocytes/macro-
phages, recruited in the subintimal space by damaged
endothelium, overload oxLDL via scavenger receptors and
perpetuate the local inflammatory response secreting
cytokines, degrading enzymes [matrix metalloproteinases
(MMPs)] as well as growth factors that stimulate smooth
muscle cell (SMC) migration and proliferation. The
continuous influx of cells into the subintimal space converts
the fatty streak into a more complex and advanced lesion in
which inflammatory cells (monocytes/macrophages, lym-
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oxLDL elicit a chronic inflammatory response by the
adaptive immune system. SMCs form a thick fibrous cap
that cover the necrotic core and avoid the exposure of
thrombogenic material to the bloodstream. The volume of
lesion grows up and protrudes into the arterial lumen
causing variable degrees of lumen stenosis. The degree of
carotid lumen stenosis is a relevant marker for the risk of
cerebrovascular disease [20, 21] even if the cause of most
clinical events should rely on thromboembolism from a
vulnerable carotid plaque [22].
The microenvironment of the plaque could elicit an
adaptive immune response able to determine a selective
recruitment of inflammatory cells. In this evolutive stage
lymphocytes, instead of macrophages, orchestrate the
immune response. The switch to a selective recruitment of
T helper type 1 (Th1) T lymphocytes represents a key point
toward plaque vulnerability/disruption. In particular Th1 T
lymphocytes promote plaque destabilization triggering
vascular inflammation and downregulating extracellular
matrix production by SMCs.
Interferon (IFN)-γ, the cytokine that characterizes the
Th1 pattern, strongly inhibits the proliferation of SMCs and
the production of interstitial collagens by vascular SMCs,
affecting the stability of the fibrous cap. In this context
activated macrophages secrete proteases that can degrade
collagen. In addition, ligation of CD40 expressed by
macrophages increases the production of matrix-degrading
proteases. Therefore the integrity of the fibrous cap is
drastically regulated by inflammatory cells which cause the
thinning of the collagen-rich fibrous cap overlying the
atheroma. The physical disruption of the protective cap will
cause the exposure of the procoagulant factors expressed
within lesions to circulating clotting factors initiating the
coagulation cascade responsible for thrombosis.
In the early phase of atherosclerosis development,
luminal size is not affected by plaque growth because of
expansion of external elastic membrane and enlargement of
vessel size, representing “positive remodelling”, known as
the “Glagov effect”. Functionally important lumen stenosis
may be delayed until the lesion occupies 40% of the
internal elastic lamina area. The preservation of a nearly
normal lumen cross-sectional area despite the presence of a
large plaque should be taken into account in evaluating
atherosclerotic disease with use of coronary angiography
[23]. With disease progression, repeated silent plaque
ruptures are followed by wound healing, resulting in
increased stenosis [24]. There is no further increase in
vessel size, but rather the plaque encroaches on the lumen,
which shrinks, representing “negative remodelling” [25].
Positive and negative arterial remodelling are both
associated with plaque physiology and clinical presentation.
Positive remodelling appears to be a feature of unstable
vulnerable plaques, which have a higher lipid content and
macrophage count, and is primarily determined by inflam-
mation, calcification and medial thinning [26, 27]. This
positive remodelling is mostly seen in patients presenting
with acute coronary and cerebrovascular syndromes (un-
stable angina, myocardial infarction, sudden death and
stroke) and is typically due to rupture of plaques with only
modest luminal stenosis (less than 75% in angiography)
[28, 29]. The risk of plaque disruption depends more on
plaque composition and vulnerability (plaque type) than on
degree of stenosis (plaque size) [30]. In contrast, negative
remodelling is associated with smoother and stable plaques
such as in patients with stable angina, but nevertheless
eventually resulting in severe stenosis.
In a study performed by Schoenhagen et al. positive
remodelling and larger plaque areas were associated with
unstable clinical presentation, whereas negative remodel-
ling was more common in patients with stable clinical
presentation. This association between the extent of
remodelling and clinical presentation may reflect a greater
tendency of plaques with positive remodelling to cause
unstable coronary syndromes [31].
The most vulnerable coronary plaques are relatively non-
stenotic (<75% cross-sectional area stenosis, normal lumina
on angiography), have a larger lipid core and an often
inflamed thin fibrous cap, and are associated with positive
remodelling [30, 32] In contrast, low-risk plaques tend to
be fibrotic and severely stenotic after a while due to
negative remodelling. In both remodelling stages, repeated
neovascularization of the intima at sites of vulnerable lipid-
rich plaques is associated with infiltration of inflammatory
cells contributing to plaque destabilization [33, 34].
Exploring the functional status of the plaque in both
remodelling stages would be therefore essential to predict
the most probable clinical complication.
Molecular events in atherosclerosis
Atherosclerosis was always considered to be a lipid storage
disease. However, recent advances in basic science have
established a fundamental role for inflammation in all
stages of this disease from initiation through progression
and ultimately to the thrombotic complications of athero-
sclerosis [35]. Hypercholesterolaemia and other risk factors
are important in approximately 90% of patients with
cardiovascular disease [36], but atherosclerosis does not
result simply from the accumulation of lipids. It is clearly
an inflammatory disease [37]. An atherosclerotic lesion can
represent different stages of an inflammatory process in the
artery; if unabated and excessive, this process will
eventually result in an advanced, complicated lesion with
plaque rupture and thrombosis. This consideration has
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diagnosis and targeting of therapy.
Endothelial cells, which under normal circumstances
prevent adhesion of leukocytes and platelets, now express
cellular adhesion molecules, chemokines and vascular cell
adhesion molecules such as vascular cell adhesion molecule 1
(VCAM-1) [35, 38–40]. In addition selectins, like P- and E-
selectin, contribute to leukocyte recruitment in atherosclero-
sis [40, 41]. These processesare partiallymediatedbynuclear
factor κB( N F - κB), one of the transcriptional controllers in
vascular inflammation and an integrator in atherogenesis, and
proinflammatory cytokines, such as interleukin 1β (IL-1β)
and tumour necrosis factor α (TNF-α).
Sites predisposed to lesion formation are branch points
of arteries, which experience flow disturbances rather than
uniform laminar flow. In these regions, the mean shear
stress is relatively low and the NF-κB pathway may be
primed for activation. Systemic risk factors would therefore
preferentially induce the expression of proatherogenic NF-
κB-dependent genes at lesion-predisposed sites. On the
other hand, a straight segment of the artery proximal to the
bifurcation is associated with a uniformly laminar blood
flow profile that may induce the expression of genes
producing atheroprotective proteins [42]. For example, the
antioxidant superoxide dismutase (SOD) combats oxidative
stress, endothelial nitric oxide synthetase (eNOS) inhibits
the activation of NF-κB and cyclooxygenase 2 (COX-2)
has an anti-inflammatory effect [43].
Once adherent to the endothelial cell, via VCAM-1
binding, leukocytes and monocytes enter the intima by
diapedesis between endothelial cells at their junctions. This
phenomenon is mediated through chemokines, such as
monocyte chemoattractant protein 1 (MCP-1) [44, 45] and
IL-8 as leukocyte chemoattractant [45–47]. Angiotensin II
promotes atherogenesis by direct activation of MCP-1 gene
expression in vascular SMCs [48]. Chemokines are sub-
divided into four families based on the position of their
cysteine residues (CC, CXC, C, CXC3). Lymphocyte
recruitment occurs through expression of three CXC
chemokines on endothelial cells as well as the expression
of their receptor, CXCR3, by all T lymphocytes within
atherosclerotic lesions. This attraction is induced by IFN-γ
that binds to the CXCR3 receptor on T lymphocytes at the
atherosclerotic lesion [49].
A recent paper by Schwarz et al. showed that wire-
mediated arterial injury induced local and systemic expres-
sion of IFN-γ-inducible protein 10 (IP-10) and monokine
induced by IFN-γ (MIG), resulting in enhanced recruitment
of CXCR3+ leukocytes and haematopoietic progenitor
cells. This was accompanied by profound activation of
mammalian target of rapamycin complex 1 (mTORC1,
playing a fundamental role in the regulation of cell viability,
translation initiation and cell cycle progression), increased
reactive oxygen species production, apoptosis and intimal
hyperplasia. In vitro, stimulation of T cells with IP-10
directly activated mTORC1 and induced generation of
reactive oxygen species and apoptosis in an mTORC1-
dependent manner. These results strongly indicate that
CXCR3-dependent activation of mTORC1 directly links
stimulation of the Th1 lymphocytes’ immune system with
the proliferative response of intimal cells in vascular
remodelling: a process that is followed by expression of
activation markers on T-cell surface such as the IL-2
receptor, CD25-CD122-CD132 heterotrimer [50].
In the intima, monocytes acquire the morphological
characteristics of macrophages and express scavenger
receptors that bind internalized lipoprotein particles. These
lipid-laden cells, known as foam cells, characterize the
early atherosclerotic lesion, the fatty streak, and secrete
proinflammatory cytokines that amplify the local inflam-
matory response in the lesion, as well as growth factors,
that stimulate the smooth muscle replication responsible for
lesion growth. Macrophage colony-stimulating factor (M-
CSF) acts as the main stimulator in this process, next to
granulocyte-macrophage colony-stimulating factor (MG-
CSF) and IL-2 for lymphocytes [51, 52]. Colony stimulating
factor 1 (CSF-1) represents a link between inflammation
and cardiovascular disease. Two distinct mechanisms were
suggested by which CSF-1, which is known to be present in
atherosclerotic lesions, may contribute to plaque progres-
sion. CSF-1 modulated the human monocyte-derived
macrophages (HMDM) transcriptome to favour a proa-
therogenic environment. CSF-1 induced expression of the
proatherogenic chemokines CXCL10/IP-10, CCL2 and
CCL7 but repressed expression of the antiatherogenic
chemokine receptor CXCR4 [53].
Human atherosclerotic plaques contain numerous T
lymphocyte cells. In a plaque, ∼40% of the cells express
macrophage markers, ∼10% are CD3+ T cells and most of
the remainder have the characteristics of SMCs [54]. T
lymphocyte cells can be activated by autoantigens, such as
oxLDL and heat-shock proteins (HSPs, both of endogenous
and microbial origin). Both autoantigens serve as the target
for autoimmune responses in inflammatory diseases and
produce cytokines that can influence the behaviour of other
cells present in the atheroma and so stimulating inflamma-
tion and plaque formation [55].
Mononuclear phagocytes play a key role in the throm-
botic complications of atherosclerosis producing degrading
enzymes, i.e. MMPs able to degrade the extracellular
matrix that gives strength to the fibrous cap [56–58].
Subsequent to cap thinning a disruption or tear in the cap
causes blood to enter the lipid core of the plaque
determining an initial phase of intraplaque haemorrhage.
Blood cells may make contact with another macrophage
product, the potent procoagulant protein tissue factor,
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expansion of the atheromatous lesion [59]. This remodel-
ling of the thrombus and the release of platelet-derived
growth factor (PDGF) and the anti-inflammatory mediator
transforming growth factor β (TGF-β) leads to fibrous
tissue formation. Eventually the macrophages congregate in
a central core in the typical atherosclerotic plaque. Macro-
phages can die in this location, some by apoptosis, so
producing the “necrotic core” of the atherosclerotic lesion.
All this happens in the beginning of intraplaque haemor-
rhage, thrombosis and necrosis that may or may not be
followed by thrombosis within the lumen [35].
A brief overview of the molecular events leading to plaque
formation (stable and unstable) is given in Figs. 1 and 2.
Non-nuclear imaging techniques for detecting
atherosclerotic plaques
For almost 50 years, contrast angiography (“luminogram”)
has been the gold standard imaging technique for athero-
sclerosis. It provides high-resolution definition of the site
and severity of luminal stenosis. However, assessment of
coronary lumen integrity is of limited value for the
detection of subclinical cardiovascular disease because, as
stated before, the artery lumen is preserved in the beginning
by outward (positive) arterial remodelling [23, 60]. Another
limitation of angiography is that diffuse atherosclerotic
disease may narrow the entire lumen of the artery and as a
result underestimate the degree of local stenosis. Furthermore
it is an invasive technique which can cause minor and major
complications.Inthe followingwedescribeother non-nuclear
invasive and non-invasive techniques for detecting athero-
sclerosis. After that we will focus on the nuclear techniques
that have been or are currently being used. Table 1 shows the
different imaging modalities and their role in the different
stages of the development of atherosclerosis.
Non-nuclear invasive imaging techniques
Intravascular ultrasound (IVUS) permits direct arterial
vascular wall imaging and delineates the thickness and
echogenicity of vessel wall structures. The standard
techniques for intravascular coronary delivery are used for
this intravascular examination. It can be a valuable
supplement to angiography. Angiography depicts only a
2-D silhouette of the lumen, whereas IVUS allows
tomographic assessment of lumen area, plaque size,
distribution and composition of the plaque. An important
potential application of IVUS is the identification of
atheromas at risk of rupture [61]. IVUS-derived residual
plaque burden is a useful predictor of clinical outcome [62].
Recent advances in IVUS technology, such as the use of
high-frequency transducers [63], radiofrequency signal
analysis [64, 65], integrated backscatter [66] and elastog-
raphy [67], have improved the capability of IVUS for plaque
characterization. However, there are limitations of IVUS.
Interpretation still relies on simple visual inspection, and
different tissue components appear quite similar. Artefacts
can adversely affect the ultrasound images and the physical
sizeofultrasound catheters (∼1mm)constitutesanimportant
limitation in imaging severe stenoses [61].
Another non-nuclear invasive technique is intravascular
MRI (IVMRI) using catheter-based imaging coils. Studies
have demonstrated its capability of differentiating plaque
components in ex vivo human and in in vivo animal lesions
[68–70]. A limitation of both aforementioned techniques is
the limited resolution of both IVUS (100–250 µm) [63–65,
67] and IVMRI (120–440 µm) [68, 69]. This precludes
accurate evaluation of relevant microstructural features,
such as thin fibrous caps (<65 µm).
Intracoronary angioscopy allows direct visualization of
the plaque surface, presence of thrombus and macroscopic
features, such as ulcerations and fissures [71, 72]. However,
this technique remains a research tool because of the
inability to examine small-caliber vessels or cross-stenotic
lesions or the different layers within the arterial wall [71].
Given its high resolution (10–15 µm, due to the use of
infrared light rather than acoustic waves), intravascular
optical coherence tomography (OCT) has great promise for
the assessment of the microstructure of the plaque [73–75]
and potentially for the quantification of macrophage content
within fibrous caps. This unique capability for fibrous cap
characterization suggests that this technology may be well
suited for identifying vulnerable plaques in patients [76].
Yabushita et al. established OCT criteria for characterizing
atherosclerotic plaques in vitro by correlating OCT images
with histology. They found a strong correlation with the
corresponding histopathology in vitro [77]. OCT exhibited
superior delineation of structural detail compared with IVUS
[78]. Limited penetration depth (1–2 mm) allows only partial
examination of larger vessels with advanced atherosclerosis.
Other limitations are the reduction of image quality when
imaging through blood or large volumes of tissue and lack of
an adequate portable source for in vivo imaging [71, 78].
Several other new technologies, such as thermography,
Raman spectroscopy and near infrared (NIR) spectroscopy,
may have diagnostic and therapeutic implications only when
combined with other catheter-based imaging techniques [71].
All of the above-mentioned techniques are invasive and
therefore not suited for screening or serial studies.
Non-nuclear non-invasive imaging techniques
High-resolution, B-mode ultrasound (US) with Doppler
flow imaging is the modality of choice for examining the
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thickness and quantitative analysis of plaque mass and area
as well as plaque characteristics, reflected by echogenicity,
can be determined [79]. The carotid intima-media thickness
(IMT) has been recognized as a surrogate measure of
atherosclerosis. Associated with CVD risk factors and with
coronary artery disease (CAD), it is a useful index of
subclinical CVD and predicts CVD outcome [80]. Ultra-
sound detection of carotid plaque helped identify asymp-
tomatic patients with advanced subclinical atherosclerosis
[81]. A study of a very large population, called the
Atherosclerosis Risk in Communities (ARIC) study, showed
Fig. 1 Plaque development is a complex cascade of events.
Endothelial injury is initiated by a variety of injurious noxae,
including hypertension, dyslipidaemia, shear stress and infections
(a). Leaky damaged endothelium allows the passage of leukocytes and
lipids into the subendothelial space. Activated endothelial cells
increase the expression of adhesion molecules and inflammatory
genes. Circulating monocytes migrate into the subendothelial space
and differentiate into macrophages (b). Macrophages take up lipids
deposited in the intima by a number of receptors, including scavenger
receptor A (SR-A) and CD36. Deregulated uptake of modified LDL
through these receptors leads to cholesterol accumulation and “foam
cell” formation. Multiple foam cells form the fatty streak and secrete
proinflammatory cytokines and MMPs. Both factors amplify the local
inflammatory response in the lesion and in the local matrix. Repeated
cycles of inflammation (c) lead to accumulation of macrophages, some
of which can die in this location producing the so-called necrotic core.
Living macrophages induce SMC proliferation and migration in the
lesion to form the fibrous cap of the advanced complicated stable
atherosclerotic lesion (“stable” plaque). T cells also play a major role
in the path of inflammation. T cells may encounter antigens such as
oxidized LDL and HSPs of endogenous or microbial origin. Several
different effector mechanisms can be elicited by immune responses
(d). The combination of IFN-γ and TNF-β upregulates the expression
of CXCR3 promoting the development of the Th1 lymphocyte ()
pathway which is strongly proinflammatory. The selective recruitment
and activation of Th1 T cells determines a potent inflammatory
cascade leading to the transition from stable to “unstable/ruptured”
plaque. During this transition we postulated the existence of a
theoretical plaque structure known as “vulnerable” plaque, very
similar to the unstable plaque except for plaque erosion/rupture. In
this context, IFN-γ strongly inhibits the proliferation of SMCs and the
production of interstitial collagens by vascular SMCs, thereby
affecting the stability of the fibrous cap (e). Activated macrophages
secrete procoagulant proteins and MMPs that can degrade collagen. In
addition, ligation of CD40 expressed by macrophages increases the
production of matrix-degrading proteases. All this leading to an
unstable or ruptured plaque (f)
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(>1mm)tonotextreme(<1mm)was5.1inwomenand1.9in
men. The relation was graded. Mean carotid IMTwas called a
non-invasive predictor of future CVD incidence [82]. For
each0.03mmincreaseperyearincarotidIMTtherelativerisk
for non-fatal myocardial infarction or coronary death was 2.2
and the relative risk for any coronary event was 3.1 [83].
Finally, the carotid IMT is a marker for early, preclinical
atherosclerosis in high-risk children and adults [84].
This technique is non-invasive, inexpensive and easily
applied, but is highly operator dependent and has low
reproducibility. Furthermore, it has no role in detecting
atherosclerosis in small arteries directly.
Where magnetic resonance imaging (MRI), X-ray
angiography and US can identify calcified deposits in
blood vessels, only electron-beam computed tomography
(EBCT) and fast-gated helical or spiral (i.e. multidetector
row or MD) CT can quantitate the amount or volume of
calcium [85]. This has a strong correlation with the extent
of atherosclerosis burden.
Histological and ultrafast CT studies support the associ-
ation of tissuedensities >130 HU withcalcified plaques[86].
Fig. 2 Atherosclerotic plaque
development (http://www.
resverlogix.com/product_
development/nexvas_platform/
nexvas_vascular_inflammation.
html)
Table 1 Different imaging modalities and their role in the different stages of atherosclerosis
Early events Luminal
stenosis
Wall
thickness
Plaque
composition
Plaque vulnerability Limitation
Rx-angiography - + - - - Invasive
IVUS - + + + - Invasive
IVMRI - - - + - Invasive
Angioscopy - - - + - Invasive, only
large vessels
OCT - - - + Thin fibrous cap Invasive, limited depth
Ultrasound - + + + - Only peripheral vessels
EBCT/MDCT - + (ce) - - Calcium quantification Resolution, cardiac
motion artefacts
MRI - + (ce) + + Neovasculature Resolution, motion artefacts
Mol + (Endothelin, lipids,
cytokines, peptides)
- - + Inflammation (macrophages,
neutrophils, lymphocytes)
activated platelets
Resolution, low specificity,
little experience
Rx X-ray, IVUS intravascular ultrasound, IVMRI intravascular magnetic resonance imaging, OCT optical coherence tomography, EBCT electron-
beam computed tomography, MDCT multidetector computed tomography, MRI magnetic resonance imaging, Mol molecular imaging
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controversy exists over the relation of calcification to
plaque vulnerability, pathology data indicate that athero-
sclerotic calcifications are frequent in acute lesions and are
associated with plaque healing after rupture, thus being a
possible marker of susceptibility to ischaemic events [87].
In the coronary arteries, the amount of coronary calcium
could be a predictor of risk of coronary events. A high
calcium score is sensitive but not a specific marker for
coronary stenosis. A negative calcium score may exclude
CVD; it has been demonstrated that in a population with
predominately intermediate likelihood of CAD, a coronary
artery calcium score (CACS) of zero excludes inducible
ischaemia on myocardial perfusion PET [88], but non-
calcified plaques can be eventually missed. The greatest
potential for CACS appears to be in the detection of
advanced coronary atherosclerosis in patients who are
apparently at intermediate risk [89, 90]. It could also be
used as an additional tool to the risk stratification of
asymptomatic individuals [91]. It was recently stated that a
stepwise approach including history, CACS and CT angiog-
raphy (CTA) can identify about 50% of the patients with
normal myocardial perfusion imaging who have a higher risk
and may benefit from aggressive medical management [92].
Coronary CTA is an emerging technology to evaluate the
lumen of the coronary arteries. Plaque burden can be either
assessed quantitatively or semi-quantitatively with CTA;
plaque location should be considered as well, as vulnerable
plaques are most often observed in proximal segments of
the coronary artery tree. To some extent, CTA also allows
assessment of plaque composition since non-calcified
plaques have low attenuation, calcified plaques high
attenuation, and mixed plaques have both non-calcified
and calcified elements. Plaque remodelling, a marker of
vulnerability, can also be appreciated by CTA [93]. The
burden of angiographic disease detected by CTA provides
both independent and incremental value in predicting all-
cause mortality in symptomatic patients independent of age,
gender, conventional risk factors and CACS [94]. The
operating characteristics of CTA support its potential role as
a tool useful in ruling out obstructive CAD and its clinical
implementation appears to positively impact conventional
coronary angiography by reducing the frequency of normal
invasive examinations [95]. Due to its excellent negative
predictive value, coronary CTA is a suitable test to exclude
significant CAD. However, given its high rate of false-
positive results, particularly in the presence of significant
coronary calcification, CTA only rarely is a real alternative
to invasive coronary angiography in clinical practice. This
was recently reported in a paper indicating that contrast-
enhanced CTA can exclude significant CAD in patients
with a low-intermediate CACS but is of limited value in
patients with a high CACS [96]. In the evaluation if carotid
plaques it has been demonstrated that CTA with multi-
detector capabilities is able to quantify total plaque area,
calcifications and fibrous tissue in good correlation with
histology whereas lipid core can only be adequately
quantified in mildly calcified plaques [97]. The proportion
of carotid plaque calcification, rather than absolute volume,
was associated with stability. Highly calcified carotid
plaques (>45%) were demonstrated to be more stable
[98]. This is in accordance with the finding that in contrast
to lipid pools, which dramatically increase stress, calcifica-
tion is supposed to reduce fibrous cap stress in atheroscle-
rotic lesions [99].
Concluding, CTA is an useful tool; however, use of CTA
in asymptomatic patients as a screening test is currently not
recommended because it has both significant radiation and
contrast administration.
Magnetic resonance imaging (MRI) has been applied in
the study of atherosclerotic disease in different ways: with
high-resolution sequences, with contrast-enhanced techni-
ques and with MR angiography (MRA) with and without
contrast injection. MRI is definitely superior to other
imaging modalities in distinguishing soft tissue contrast.
High-resolution MRI has the potential to non-invasively
image the human coronary artery wall, but coronary
imaging by MR has been limited by artefacts related to
blood flow, motion and low spatial resolution. Fayad et al.
developed an in vivo high-resolution black-blood magnetic
resonance method to investigate the morphological features
of both normal and atherosclerotic human coronary arteries
and they found a significant difference in the average
maximum coronary wall thickness between the two [100].
However, this technique uses breath-holding strategies,
which are often difficult to implement in patients, especially
those with pulmonary or CAD. Botnar et al. used a free-
breathing MR method that demonstrated a significantly
greater coronary wall thickness and wall area in patients
with angiographic CAD [101]. Likewise, Kim et al.
assessed increased coronary vessel wall thickness with
preservation of lumen size in patients with non-significant
CAD using free-breathing black-blood three-dimensional
cardiovascular magnetic resonance, consistent with the
Glagov principal [102]. This could be of use in quantifying
subclinical disease.
Cai et al. showed that high-resolution multi-contrast
MRI is capable of classifying intermediate to advanced
human atherosclerotic lesions in the human carotid artery
and is also capable of distinguishing advanced lesions from
early and intermediate plaques (according to the American
Heart Association classification) [103]. Hatsukami et al.
introduced the use of bright blood imaging (i.e. 3-D fast
time-of-flight imaging) for the visualization of fibrous cap
thickness and morphological integrity. In a prospective in
vivo and in vitro serial examination of human carotid artery
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imaging and histological findings in distinguishing between
thin intact, thick intact and ruptured fibrous caps [104].
Compared with asymptomatic plaques, symptomatic pla-
ques had a higher incidence of fibrous cap rupture and
juxtaluminal haemorrhage or thrombus [105].
The reproducibility of MRI was assessed by the HIgh-
Resolution magnetic resonance Imaging in atherosclerotic
Stenosis of the Carotid artery study group (HIRISC).
Reproducibility of MRI for identifying and quantifying
carotid plaque components is overall acceptable, but there
is still significant variability that should be taken into
account in the design of prognostic studies and clinical
trials; in particular reproducibility for fibrous cap identifi-
cation needs to be improved [106]. Serial MRI scans
proved feasibility in monitoring changes in atherosclerotic
plaque composition. This could have potential for following
patients with known or suspected atherosclerotic CAD or
for serial evaluation after pharmacological intervention
[107–109].
Other studies suggested a link between enhancement
patterns in contrast-enhanced MRI (ce-MRI) and neovascu-
lature [110, 111]. Kerwin et al. used dynamic ce-MRI for
quantitative measurement of the extent of neovasculature
within carotid plaques, providing a potential means to
identify plaque vulnerability [112]. Novel MR contrast
agents were developed, like fibrin-targeted paramagnetic
nanoparticles, that could allow sensitive detection and quan-
tification of occult microthrombi within the intimal surface of
atherosclerotic vessels, therefore allowing in an early stage the
localization of fibrin and direct identification of vulnerable
plaques [113, 114]. The first reports seem promising, but in
the last few years no further results were mentioned.
MR angiography has been studied for years and has
undergone numerous technical improvements and innova-
tions. Coronary MRA techniques were reviewed by Fayad
et al. The sensitivity and specificity was persistently lower
as compared to traditional contrast coronary X-ray angiog-
raphy and each of the techniques suffers from artefacts due
to cardiac motion and limitations in spatial and temporal
resolution [115]. Methods, like routine administration of an
oral β-blocker before scanning, were applied to minimize
motion artefacts [116]. Till now, the results are not
satisfying enough. MRA with gadolinium injection is
routinely applied in clinical practice for the study of larger
vessels such as the carotid artery, aorta and peripheral
vessels. It represents, in most cases, the second diagnostic
tool after Doppler ultrasound. For carotid atherosclerotic
disease MRA with contrast injection represents the best
diagnostic tool for visualization of the vascular tree from
the aortic arch to the intracranial vessels. It is frequently
performed with MRI of the brain for a complete vascular
evaluation.
All of the above-mentioned non-nuclear imaging modal-
ities allow early detection of plaque formation, but they do
not provide any information on the actual risk of plaque
rupture, the main cause of acute ischaemic events. These
vulnerable plaques are often only mildly stenotic and
histologically characterized by a large lipid or necrotic core,
a thin fibrous cap, intraplaque haemorrhage and presence of
activated macrophages [32, 37, 59]. Moreover, a study by
Ojio et al. revealed that microthrombus formation precedes
acute myocardial infarction or stroke by days to months,
providing an opportunity to intervene and prevent serious
complications [117].
These items emphasizes the need to detect the most
vulnerable plaques at an early stage. Non-nuclear imaging
modalities are not capable of doing so.
Nuclear imaging techniques for detecting atherosclerotic
plaques
Many radiopharmaceuticals have been developed on the
basis of molecules and cells involved in atherogenesis.
These radiopharmaceuticals can be divided into three major
groups, based on their target cells (see Table 2).
Radiopharmaceuticals targeting atherosclerotic lesion
components
Already in the 1980s the feasibility of localizing human
atherosclerotic plaques with
99mTc-labelled LDL was tested
in patients. It did accumulate in some atherosclerotic
plaques (found in carotid endarterectomy specimens) and
in a few patients the accumulation was sufficient for
detection by gamma camera imaging. However, the amount
of LDL that accumulated was very low, depended on the
lesion composition and coronary lesions could not be
visualized because of residual blood pool activity [118].
Later on, reports suggested that oxidized LDL (oxLDL,
an atherogenic lipid) played a major role in the pathogen-
esis of atherosclerosis. A technique was developed to
oxidize autologous LDL and to label it with
99mTc.
Biodistribution data demonstrated rapid clearing of
99mTc-
oxLDL from circulation, accumulation mostly by organs
rich in macrophages, and it could be detected at the level of
carotid plaques [119].
Activated macrophages are densely present in athero-
sclerotic lesions. They are known to express scavenger
receptors for modified LDL. Acetylated LDL (ac-LDL)
competes with oxLDL for access to these receptors.
99mTc-
ac-LDL visualized densely localized scavenger receptor
sites constituted by activated macrophages at the site of
inflammatory lesions and therefore appeared promising for
the scintigraphy of atherosclerotic lesions [120].
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found to be mediating the biological effects of oxLDL in
the process of plaque formation. Moreover, animal studies
demonstrated that LOX-1 expression in atherosclerotic
plaques was positively correlated with plaque instability in
vivo, thus suggesting that this receptor may play an
important role in the destabilization of atherosclerotic
plaques [121]. Therefore,
99mTc-anti-LOX-1 monoclonal
IgG was designed, prepared and its usefulness as an
atherosclerosis imaging agent was tested in mice and
rabbits. The atherosclerotic lesions were divided into four
categories using the recommendations of the American
Heart Association where type IV lesions contained thin
fibrous connective tissue and a dense accumulation of
extracellular lipid and foam cells, corresponding to vulner-
able lesions in human atherosclerotic plaques. Indeed, the
level of
99mTc-LOX-1 monoclonal IgG accumulation in
grade IV atheroma was significantly higher than that in
neointimal lesions or other, more stable lesions [122].
Nuclear imaging of LOX-1 expression may be useful for
predicting atheroma at risk for rupture.
The free radicals O2
- and
.NO are generated by blood
vessels and can rapidly react to produce a peroxynitrite
anion (ONOO
-), a powerful oxidant that modifies lip-
oproteins making them more atherogenic. Peroxynitrite-
modified β-VLDL labelled with
99mTc was studied in vitro
in rabbits. It was found to be an interesting tool to study
lipoprotein accumulation in organs (liver, kidneys) and
maybe also in atherosclerotic plaques [123].
MDA2 is a monoclonal mural antibody to epitopes that
are present on oxLDL, but not on normal LDL.
125I-
labelled MDA2 can be used to detect atherosclerotic lesions
in rabbit aortas and
99mTc-labelled MDA2 to image
atherosclerotic lesions in living rabbits [124].
Uptake of
99mTc-MDA2 in plaques was significantly
higher than in normal aortas and it also correlated with
aortic weight and percent atherosclerotic surface area in
rabbits and mice. Moreover, it also reflected reduced plaque
oxLDL content after hypocholesterolaemic intervention
(diet) [125]. Because these oxidation-specific antibodies
showed these results for atherosclerotic lesions, the authors
developed a human oxidation-specific antibody, called
IK17, which was labelled with
125I. Restricted immunologic
reactions, higher in vivo plaque uptake and improved lesion
to blood ratio was found, compared to the murine antibody
[126].
The last tracer specific for atherosclerotic lesions
components is
99mTc-endothelin derivative. Vascular SMCs
express endothelin receptors, reason to see if an endothelin
derivative called ZK167054 could be used for imaging of
experimentally induced atherosclerosis. The results indicated
that in vivo imaging of atherosclerosis with an endothelin
derivativeisafeasiblemethodfordetectingandcharacterizing
atherosclerotic arterial wall lesions at early stages in a rabbit
restenosis model [127, 128].
Radiopharmaceuticals to detect atherosclerotic
inflammation
Several cytokines, chemokines and their receptors, respon-
sible for early events in atherosclerosis, can be directly or
indirectly labelled with radionuclides and therefore visual-
ized in vivo. These chemokines have low molecular weight,
short half-life and rapid plasma clearance, all favourable
radiopharmaceutical features [129].
Monocytes and macrophages, predominant cell types in
acute and chronic inflammation, are attracted to and
activated by monocyte chemotactic peptide 1 (MCP-1).
125I-MCP-1 has been tested in normal mice and in
atheroma-rich rabbits and the uptake correlated with the
number of macrophages per unit area [130]. In another
study in rats,
99mTc-MCP-1 was found to localize only in
zones of subacute inflammation, reflecting the density of
macrophages and monocytes [131]. Radiolabelled MCP-1
may be a useful tracer for imaging monocyte/macrophage-
rich atherosclerotic lesions in the stage of subacute
inflammation.
IL-8 is a chemotactic cytokine that binds with a high
affinity to receptors expressed on neutrophils. It plays an
important role in cell recruitment during acute inflamma-
tion. Various animal models showed specific and rapid
accumulation of
99mTc-IL-8 in infectious and inflammatory
foci [132, 133]. Labelling with
123Ig a v et h es a m e
promising results [134]. Recently,
99mTc-IL-8 was also
tested in 20 patients. Injection was well tolerated and
99mTc-IL-8 scintigraphy seemed to be a promising new tool
for the detection of infections in patients as early as 4 h
after injection [135]. It has not been tested in atheroscle-
rosis yet.
IL-1 is also a proinflammatory cytokine with a high
affinity to a specific receptor expressed on monocytes and
lymphocytes. It was one of the first cytokines developed for
imaging acute inflammation. Labelled with
123Io r
125I, IL-1
was tested in different animal models of infection or sterile
inflammation [136]. There was a highly specific uptake at
the infection site, but due to side effects (hypotension,
headache) even in low doses, the radioiodinated IL-1 has
never been tried in humans.
Consequently, a radiolabelled IL-1 receptor antagonist
(IL-1 RA) was developed, with the same binding affinity
for IL-1 receptors but without any biological activity.
However, in mice the abscess uptake of IL-1 RA was much
lower than that of IL-1 because of interaction with serum
proteins [137]. This was also seen in a rabbit infection
model; however, the observation of radiolabelled IL-1 RA
in the infectious focus was important [138]. After these
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123I-IL-1 RA was studied in patients with
rheumatoid arthritis (RA) and to assess whether it is
suitable for scintigraphic visualization of synovitis .
123I-
IL-1 RA was able to image inflamed joints but autoradio-
graphic studies did not indicate that the joint accumulation
of radiolabelled IL-1 RA was due to specific IL-1 receptor
targeting [139]. The uptake behaviour was similar to those
of non-specific labelled agents, so it seems that radio-
labelled IL-1 RA is not suitable for scintigraphic detection
of inflammation and therefore it will play no role in
imaging atherosclerosis.
IL-2 has a high affinity for IL-2 receptors expressed by
activated lymphocytes during inflammation. IL-2 is a growth-
promoting factor of T lymphocytes and has effects on a wide
variety of cells such as CD4+ T cells, CD8+ T cells, B cells
and natural killer cells. Most prominently, it is important in T-
cell activation and inflammatory consequences thereof [140].
Both
99mTc--a n d
123I-labelled IL-2 have been successfully
used in several diseases characterized by a chronic lympho-
cytic infiltration, such as Crohn’s disease, coeliac disease,
type 1 diabetes and autoimmune thyroid diseases [141].
Higher serum IL-2 levels are associated with increased
carotid artery IMT, a predictor of stroke and vascular
disease [142].
99mTc-IL-2 is therefore also used for imaging
carotid atherosclerosis in humans. Fourteen patients (16
plaques) eligible for endarterectomy underwent
99mTc-IL-2
scintigraphy before surgery. Another nine patients (13
plaques) received atorvastatin or a standard hypocholester-
olaemic diet and scintigraphy was performed before and after
3m o n t h so ft r e a t m e n t .
99mTc-IL-2 accumulated in vulnerable
carotid plaques and the accumulation correlated with the
amount of IL-2R+ cells within the plaque (measured ex vivo
by histology). Also, the amount of
99mTc-IL-2 within the
plaque was influenced by lipid-lowering treatment with a
statin [143].
99mTc-IL-2 is a very promising tracer that could provide
useful information for the selection of infiltrated vulnerable
plaques at risk of rupture. There are no significant biological
side effects at the low dose used for imaging purposes.
However, it is not yet commercially available and a major
drawback is the complexity of the labelling procedure,
although
99mTc-IL-2 can be easily prepared [141].
Other cytokines have been labelled with iodide, but the
applications remain uncertain.
125I-IL-3 has only been tried
for in vitro binding studies without further application in
humans.
123I-IL-6 was compared to iodinated IL-1. The
degree of IL-6 uptake in different animal models of acute
inflammation was much lower than IL-2. Therefore, the use
of radioiodinated IL-6 was abandoned.
123I-IL-12 was
successfully tested in a mouse model of autoimmune colitis
and could be a possible alternative to IL-2 [141].
All of the above-mentioned tracers are SPECT tracers. The
well-known PET tracer
18F-fluorodeoxyglucose (
18F-FDG)
has the possible advantage that it can provide absolute
quantification and better resolution than the SPECT tracers.
FDG is a glucose analogue that is trapped in cells in
proportion to the cells’ metabolic activity.
18F-FDG is
retained within plaque macrophages more avidly than within
other plaque elements [144]. A good reproducibility was
reportedinagroupofpatientsthatunderwentcarotidarteryand
aortic imaging, with high inter- and intraobserver agreement
and low variability of
18F-FDG uptake over 2 weeks [145].
Results in the iliac and femoral arteries were also highly
reproducible; however, the FDG uptake in the carotid
arteries was significantly higher than in both iliac and
femoral vessels [146]. In 30% of patients with documented
carotid atherosclerosis inflammation was detected by FDG
PET imaging. This raises the possibility for this non-
invasive metabolic imaging modality to aid in the risk
stratification and selection of appropriate therapy. Large
prospective studies are necessary to determine if the
detection of inflamed plaque by
18F-FDG PET is useful
for predicting future CVD [147]. An example of FDG PET
imaging in atherosclerosis can be seen in Fig. 3.
Radiopharmaceuticals to detect thrombosis
Radiolabelled platelets are theoretically the best pool to
image the platelet-rich thrombus development in a lesion.
Table 2 Possible radiopharmaceuticals for imaging atherosclerosis
Radiopharmaceutical Target
Atherosclerotic lesion components
99mTc-LDL/oxLDL/ac-LDL Foam cells
99mTc-LOX-1-mAb Foam cells
99mTc-β-VLDL Lipoproteins
125I/
99mTc-MDA2,
125I-IK17 Lipids
99mTc-endothelin Endothelin
Inflammation
99mTc /
125I-MCP-1 Macrophages and monocytes
99mTc/
123I-IL-8 Neutrophils
123I-IL-1 RA Monocytes and lymphocytes
123I- or
99mTc-IL-2 Lymphocytes
18F-FDG Metabolic glucose activity
Thrombosis
111In-platelets Platelets
99mTc-apcitide/P280 Activated platelets
99mTc-DMP444 Activated platelets
99mTc-fibrin-binding
domain (FBD)
Fibrins
99mTc-labelled fibrin
α-chain peptide
Fibrins
Apoptosis
99mTc-annexin V Apoptotic cells
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choice. Already in the 1980s there was enthusiasm about
this technique because platelet accumulation was related to
the surface characteristics and severity of carotid lesions,
especially in the presence of ulceration [148]. However, the
use of this technique is lowered because of the low signal to
noise ratio with the circulating blood pool and the lack of
documentation of the underlying pathological condition. In
2001, the performance of
111In-platelet scintigraphy with
blood pool subtraction was compared to ultrasound Doppler
techniques and carotid artery plaque specimens removed at
the time of carotid endarterectomy in 22 patients.
111In-platelet scintigraphy was found to be an accurate
non-invasive diagnostic tool to detect thrombotic com-
plications in carotid plaques [149]. Despite these find-
ings, prospective studies with this technique have not yet
been performed.
99mTc-radiolabelled peptides have been developed for
thrombosis imaging, targeting either activated platelets [the
glycoprotein (GP) IIb/IIIa receptor and phosphatidylserine]
or fibrin (C-terminal portion of the γ-chain of fibrin) [150].
99mTc-apcitide (also known as
99mTc-P280) is a radio-
labelled peptide that binds with high affinity and specificity
to the GP IIb/IIIa receptors expressed on the activated
platelets that are involved in acute thrombosis [151]. It
detects most acute thrombi and has potential utility in
suspected recurrent deep venous thrombosis (DVT) [152].
It has been approved by the Food and Drug Administration
(FDA) for the clinical detection of acute DVT.
Another agent developed for targeting activated platelets
is
99mTc-DMP444, which is another GP IIb/IIIa receptor
antagonist. It has been shown to be actively incorporated into
arterial and venous thrombi in DVTand pulmonary embolism
(PE). It has also been used in imaging infective endocarditis.
Af i b r i nα-chain, N-terminal peptide that binds to the C-
terminalportionoftheγ-chainoffibrinhasbeenmodifiedand
labelled with technetium. The resultant peptide
99mTc-labelled
fibrin α-chain binds to rabbit, dog and human fibrin in large
quantities and delineates experimental DVT and PE in
rabbits. This agent is worthy of further investigation [153].
Another agent for targeting fibrin that has been investi-
gated is
99mTc-fibrin-binding domain (FBD), a radiolabelled
fibrin-binding domain of fibronectin. It has shown a high
diagnostic accuracy in the detection of DVT [154]. The role
in atherosclerosis still remains unclear.
Radiopharmaceuticals to detect apoptosis
Finally, annexin V, an endogenous human protein, binds
with high affinity to phosphatidylserine. Labelling with
technetium makes it possible to assess non-invasively the
early stage of apoptosis and to provide information about
disease progression or regression. The use of
99mTc-annexin
V has been described in monitoring therapies in acute
Fig. 3 Upper left: CT image
transverse view, atherosclerotic
plaque in widened abdominal
aorta. Upper right: fused FDG
PET and CT, transverse view,
uptake in atherosclerotic lesion
in abdominal aorta. Lower left:
CT image coronal view (same
patient), multiple atherosclerotic
lesions in abdominal aorta.
Lower right: fused FDG PET
and CT, coronal view, FDG
uptake in atherosclerotic lesions
in abdominal aorta
2392 Eur J Nucl Med Mol Imaging (2010) 37:2381–2397myocardial infarction and accumulates in affected joints in an
experimental model of rheumatoid arthritis [155]. Apoptosis
is commonly observed in advanced atherosclerotic lesions. A
recent study in a rabbit model showed higher
99mTc-annexin
V accumulation in grade IV atheroma than in other more
stable lesions.
99mTc-annexin V may be useful in identifying
atheroma at risk for rupture and also possibly in assessing
response to anti-atherosclerotic therapy [156].
Future perspectives
The identification of major, causal risk factors for the
development of atherosclerosis provide physicians reliable
tools to identify individuals who are at high risk for
atherosclerosis-related clinical events. However, the quantita-
tive risk assessment would be significantly improved if
atherosclerotic plaque burden could be assessed more directly.
Non-nuclear imaging modalities have a lot of possibilities, but
are not able to look at early events and plaque vulnerability.
The emerging area of nuclear imaging techniques can provide
measures of biological activity of atherosclerotic plaques,
thereby improving the prediction of clinical events. Many
tracers already have been studied and are based on atheroscle-
rotic lesion components, inflammation and thrombosis. In
recent years there has been a major improvement in tracer
development for inflammation with very promising results.
Especially
99mTc-IL-2 has been successfully used in several
inflammatory diseases. Till now all of these radionuclides are
SPECT tracers. PET tracers have advantages over SPECT
tracers. They can provide absolute quantification and a better
resolution. SPECT/CT and PET/CT cameras can also add to
better anatomical mapping. There is a lack of correlation
between CCAS, coronary artery stenosis and vulnerability of
the plaque. The integration of anatomical and physiological
information of the plaque using PET/CT with specific plaque
target agents may provide additional information for the
clinician by the improved risk stratification and diagnostic
accuracy of integrated techniques. Coupling cytokines with
PET radionuclides seems to be very promising in the future.
Especially
18F-IL-2 could have great potential. At present,
there is no special tracer that can be called the diagnostic tool
to diagnose or predict stroke or infarction in high-risk patients.
Prospective randomized trials are necessary to evaluate more
precisely the clinical usefulness of these nuclear techniques
with these tracers. In future, these tracers could theoretically
also be used as targeted therapy to combat CVD.
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